Inhibikase Therapeutics, Inc. announced the appointment of David McIntyre as its new Chief Financial Officer, effective April 14, 2025. Mr. McIntyre brings over two decades of executive experience in the life sciences sector.
Mr. McIntyre has held numerous C-suite level roles at both public and private biotech and medical device companies, including Anthos Therapeutics, Inc. and HeartWare International, Inc. He also served as a Partner at Apple Tree Partners, a multi-billion-dollar life sciences venture capital fund.
His expertise in financial strategy and corporate governance is expected to be leveraged as Inhibikase continues to advance its lead product candidate, IKT-001, for Pulmonary Arterial Hypertension patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.